J R Starr1, G Tabacco1,2, R Majeed1, B Omeragic1, L Bandeira1,3, M R Rubin4. 1. Department of Medicine, Metabolic Bone Diseases Unit, Division of Endocrinology, College of Physicians & Surgeons, Columbia University, 630 W. 168th St., PH8W-864, New York, NY, 10032, USA. 2. Unit of Endocrinology and Diabetes, University Campus Bio-Medico, Rome, Italy. 3. Fleury Group, Sao Paulo, SP, Brazil. 4. Department of Medicine, Metabolic Bone Diseases Unit, Division of Endocrinology, College of Physicians & Surgeons, Columbia University, 630 W. 168th St., PH8W-864, New York, NY, 10032, USA. mrr6@columbia.edu.
Abstract
PTH levels might be associated with bone material strength as measured by impact microindentation. Resistance to microfracture is decreased in hypoparathyroidism and appears to be associated with more severe disease and to improve with PTH replacement. INTRODUCTION: PTH is a key regulator of bone structure and remodeling. When PTH is absent in hypoparathyroidism (HypoPT), bone mass is increased and remodeling is decreased. In addition to bone structure and remodeling, bone material properties contribute to fracture resistance. Yet little is known about the relationship between PTH and bone material properties. Impact microindentation provides a clinical assessment of microfracture resistance, measured as the bone material strength index (BMSi). METHODS: Case-control cross-sectional study of PTH levels and in vivo BMSi measurement by impact microindentation at the anterior tibia in HypoPT patients (n = 17) and in controls matched for age, sex, and menopausal status (n = 17), with follow-up in a subgroup of HypoPT patients (n = 5) after recombinant human parathyroid hormone (1-84) [rhPTH(1-84)] treatment. RESULTS: BMSi was positively associated with PTH levels in controls (r = 0.58, p = 0.02) and was 11% lower (p = 0.01) in HypoPT patients as compared with controls. In HypoPT, lower BMSi was associated with a trend toward greater supplemental calcium doses (p = 0.07). BMSi increased after rhPTH(1-84) treatment in the HypoPT patients who underwent repeat microindentation. CONCLUSIONS: PTH levels might be associated with bone material strength, although other factors might be contributory. In HypoPT, resistance to microfracture is decreased and may be associated with greater supplemental calcium doses and might increase with PTH replacement. It remains to be determined whether changes in bone remodeling and microarchitecture contribute to the effects of PTH on microfracture resistance.
PTH levels might be associated with bone material strength as measured by impact microindentation. Resistance to microfracture is decreased in hypoparathyroidism and appears to be associated with more severe disease and to improve with PTH replacement. INTRODUCTION:PTH is a key regulator of bone structure and remodeling. When PTH is absent in hypoparathyroidism (HypoPT), bone mass is increased and remodeling is decreased. In addition to bone structure and remodeling, bone material properties contribute to fracture resistance. Yet little is known about the relationship between PTH and bone material properties. Impact microindentation provides a clinical assessment of microfracture resistance, measured as the bone material strength index (BMSi). METHODS: Case-control cross-sectional study of PTH levels and in vivo BMSi measurement by impact microindentation at the anterior tibia in HypoPTpatients (n = 17) and in controls matched for age, sex, and menopausal status (n = 17), with follow-up in a subgroup of HypoPTpatients (n = 5) after recombinant human parathyroid hormone (1-84) [rhPTH(1-84)] treatment. RESULTS: BMSi was positively associated with PTH levels in controls (r = 0.58, p = 0.02) and was 11% lower (p = 0.01) in HypoPTpatients as compared with controls. In HypoPT, lower BMSi was associated with a trend toward greater supplemental calcium doses (p = 0.07). BMSi increased after rhPTH(1-84) treatment in the HypoPTpatients who underwent repeat microindentation. CONCLUSIONS:PTH levels might be associated with bone material strength, although other factors might be contributory. In HypoPT, resistance to microfracture is decreased and may be associated with greater supplemental calcium doses and might increase with PTH replacement. It remains to be determined whether changes in bone remodeling and microarchitecture contribute to the effects of PTH on microfracture resistance.
Entities:
Keywords:
Bone material strength; Hypoparathyroidism; Impact microindentation; rhPTH(1-84)
Authors: Robert Güerri-Fernández; Elisabet Lerma-Chippirraz; Ana Fernandez Marron; Natalia García-Giralt; Judit Villar-García; Jade Soldado-Folgado; Alicia González-Mena; Marta Trenchs-Rodríguez; Ana Guelar; Adolfo Díez-Pérez; Todd T Brown; Hernando Knobel Journal: AIDS Date: 2018-04-24 Impact factor: 4.177
Authors: Leonardo Mellibovsky; Daniel Prieto-Alhambra; Fernando Mellibovsky; Roberto Güerri-Fernández; Xavier Nogués; Connor Randall; Paul K Hansma; Adolfo Díez-Perez Journal: J Bone Miner Res Date: 2015-06-11 Impact factor: 6.741
Authors: Mishaela R Rubin; Hua Zhou; Natalie E Cusano; Rukshana Majeed; Beatriz Omeragic; Maximo Gomez; Thomas L Nickolas; David W Dempster; John P Bilezikian Journal: J Bone Miner Res Date: 2018-08-16 Impact factor: 6.741
Authors: Mishaela R Rubin; David W Dempster; Hua Zhou; Elizabeth Shane; Thomas Nickolas; James Sliney; Shonni J Silverberg; John P Bilezikian Journal: J Bone Miner Res Date: 2008-12 Impact factor: 6.741
Authors: R Rudäng; M Zoulakis; D Sundh; H Brisby; A Diez-Perez; L Johansson; D Mellström; A Darelid; M Lorentzon Journal: Osteoporos Int Date: 2015-12-02 Impact factor: 4.507
Authors: Manuela Schoeb; Elizabeth M Winter; Maria A Sleddering; Mirjam A Lips; Abbey Schepers; Marieke Snel; Natasha M Appelman-Dijkstra Journal: J Clin Endocrinol Metab Date: 2021-06-16 Impact factor: 5.958